Improved pulmonary function following pirfenidone treatment in a patient with progressive interstitial lung disease associated with systemic sclerosis

Lung India

Volumn 32, Issue 1, 2015, Pages 50-52

  Udwadia, Zarir F ^a   Mullerpattan, Jai B ^a   Balakrishnan, Canchi ^a   Richeldi, Luca ^b  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Interstitial lung disease; pirfenidone; systemic sclerosis

Indexed keywords

AZATHIOPRINE; CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PIRFENIDONE; SCL 70 ANTIBODY;

ADULT; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE COURSE; DYSPHAGIA; DYSPNEA; FEMALE; GENERAL CONDITION DETERIORATION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG FUNCTION; OFF LABEL DRUG USE; OXYGEN DESATURATION; OXYGEN SATURATION; SKINFOLD; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 84928602794     PISSN: 09702113     EISSN: 0974598X     Source Type: Journal    
DOI: 10.4103/0970-2113.148451     Document Type: Article

References (5)

1. Varga J, Abraham D. Systemic sclerosis: A prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
2. Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008; 590: 400-8.
3. Miura Y, Tsunoda Y, Tanaka T, Takoi H, Yatagai Y, Rin S, et al. The efficacy of pirfenidone in scleroderma related interstitial lung disease. Eur Respir J 2012; 40: Suppl 56, P3652.
4. Nagai S, Hamada K, Shigematsu M, Taniyama M, Yamauchi S, Izumi T. Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern Med 2002; 41: 1118-23.
5. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al.: CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011; 377: 1760-9.